Kailera Therapeutics, Inc. Common Stock (KLRA · NASDAQ)
KLRA · MARKET VIEW
Market view · as of Aug 3, 2026
Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-3.65
vs $-0.55 est · miss
52-wk position
2.2%
-34.8% vs 52w high · -23.0% 1mo
Price (last ~year)
Kailera Therapeutics (KLRA) carries a market capitalization of $2.19 billion, with shares trading at $16.94 following a 30.2% decline over the last three months. The pre-revenue biotechnology firm reported an operating loss of $84.7 million for the quarter ending March 31, 2026, resulting in a free cash flow deficit of $68.3 million. With $111.8 million in cash and $10.5 million in total debt, the stock is currently trading at an RSI of 26 and 19.8% below its 200-day moving average.
Valuation
- Market cap
- $2.19B
- Analyst target
- $42.6
Quality & returns
- Operating margin
- 0.0%
- Profit margin
- 0.0%
- ROE
- -36.9%
- ROA
- -22.7%
Price movement
- Last
- $16.94
- 1-month
- -23.0%
- 3-month
- -30.2%
- RSI (14)
- 26
- vs SMA200
- -19.8%
- 52-wk position
- 2.2% -34.8% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $0 | $-84.7M | $-78.9M | $-84.6M |
| 2025-03-31 | $0 | $-20.5M | $-18.0M | $0 |
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)
Other snapshots
Aug 31Aug 3